Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

239

Participants

Timeline

Start Date

October 27, 2022

Primary Completion Date

December 13, 2023

Study Completion Date

December 13, 2023

Conditions
Social Anxiety Disorder
Interventions
DRUG

Cannabidiol oral solution

CBD 150 mg BID

DRUG

Cannabidiol oral solution

CBD 300 mg BID

DRUG

Placebo

Placebo BID

Trial Locations (17)

10036

EPI-CBD-001-Site, New York

EPI-CBD-001-Site, Rochester

11516

EPI-CBD-001 Site, Cedarhurst

32256

EPI-CBD-001 Site, Jacksonville

32751

EPI-CBD-001 Site, Maitland

32801

EPI-CBD-001 Site, Orlando

33319

EPI-CBD-001 Site, Lauderhill

60640

EPI-CBD-001 Site, Chicago

73106

EPI-CBD-001 Site, Oklahoma City

76309

EPI-CBD-001 site, Wichita Falls

90720

EPI-CBD-001 Site, Los Alamitos

91316

EPI-CBD-001 Site, Encino

91945

EPI-CBD-001 Site, Lemon Grove

92056

EPI-CBD-001-Site, Oceanside

95124

EPI-CBD-001 site, San Jose

97210

EPI-CBD-001 Site, Portland

98007

EPI-CBD-001 Site, Bellevue

Sponsors

Lead Sponsor

All Listed Sponsors
lead

EmpowerPharm Inc.

INDUSTRY